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This finding was very similar to the 34% reduction in peak CK seen in 
patients with preinfarction angina in the study of Anzai er al. 
In conclusion, published reports remain conflicting as to whether 
prcinfarction angina is associated with improved clinical outcome. The 
protective effect suggested by thz study of Anzai et al. may be real. or 
it may simply refkxt a higher use of aspirin. Further multivariatc 
analysis is needed to clarity this isue. 
Refemmes 
Barron and Viskin suggested that the beneticial effect of przinfarclion 
angina in our study (I) might be caused by the higher in.zideoce of 
aspirin use in patients with that. without preinfar&tion angina, refe;ring 
to the recent findmgs that previous aspirin use was associated with a 
shifttowardalesssevereclinical~ltawnewiththanwithoutaspirinu~ 
in patients with acute coronary syndrome (2). We agree with the 
amccpt itself that prior use of aspirin diminishes the wverity of acute 
ischemic syndrome. 
However, :hcrc was actually no difference in aspirin use bcfore 
infarction between patients with and without preinfarction angma in 
our study (5 [3W] of 148 vs. 5 IS%] of %), Our studj population are 
quite different from those reported by Garcia-Dorado et al. (2). We 
limited the study population to patients with first 0 wave mFardial 
infarction in contrast to the stu& of Garcia-Dorado et al. (2). which 
included a broad spectrum of patients with non-Q wave myocardial 
infar&m as well as &stable angina. Two explanations arc pcrsible for 
the fact that the iocidencz of prior use of antipiatelet agents was 
unexpectedly low in our studyz i) A large portion of the study 
population had a history of angina < 1 month before infarction. More 
precisely, 55’76 of the patients with preinfardion angina had primary 
unstable angina tha! had developed within I Fk of infarct&n (I). In 
such casz+ it seems to be ditlicult to initiate rherapy, including 
antiplatelet agents, before the onset of myncardial infarction. ‘&ii is in 
amtmst to patients with a prior infarction or non-Q wave infarction 
wha havt a bttgstandii histoty of effort aegitm &c&d with anti- 
platelet agents. 2) As Garcia-Dora&? et al pointed out, patients uith 
The optimal management rtratep for inldnt\ Ullh wprd*entrruiar 
tachycardii is a contrcnersial wbjecz in @IL! ti card&@. The 
recent article in the ,wmal b O’SuIl?.~an er al. t 1 I’ p&d a new 
approach using flecainide for the prevention of rccurrcncc of w 
praventricular txhycardia m mfaq. However, in thee ~IXX&XI. the 
authors misrepresented data m a paper from our irtsutution wnczm- 
ing the use of catheter ablation for mcdiity rcfrzt* .supraventti- 
uiar tacwi in infamy. The authors state that “medica@ refrac- 
tory- uchycardii is often cited as a reason to use radiiofrcquency 
catheter ablation in infants and small &i&en and that thcsc children 
with “medically refractory- arrhythmias have often been treated onl) 
with digotin and propran&. After this statement. the) cite :he report 
from our institution (2). A cursor) rL*xw of that repon would hae 
sbn that in ever? infant and mail &dd who underwent catbcter 
ablatton at our institution, cla5s IC 0T Ill antia+thmic agenl therapy, 
alone or in combination. had failed. Since our +3 of perform4 
surgery for supraventticular arrbyIhmids. we have rescr+ed nonphar- 
macdogic therapy in this age gmup for th@se with failed intensive 
phammco@ii thcmm or a life-threatenir. event (3). We have 
continued to use this pbilosoatry with regard to catheter abiition and 
to date have never performed athcter ablatton in an) infant m whom 
on@ propranolol or dtgoxin therap! had been inekc?zvc. Present&. 
Mta. 
prior use of aspirin resulting in non-Q wave infarction bad hoen 
excluded from ana@is in our smdy. and therefore patemr who 
developd Q wave Infarction ma) be luurciatcd with a k*u incidem of 
aspirin use before mfarction. For thcr rcasom. the benefmal ctfvctr 
of preinfarction angina tinnot be attnhuted to the yor\lMe differcncer 
in the u*e of carthovax-ular medication\ 
indications for Catheter Ablation in Infants 
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our omaunes for radiofrequenq catheter ahfation in infants and small 
cbddm continue to show a 90% &cacy, with no major compkations 
reported. 
We believe that there is a morbidity and mortahty, albeit sn8ail. 
from the medical management of supraventricular tacbycardir in 
fnfancy and cbifdbood. At the Medical University of South Carolina, 
we have used aggmmhe pharmacologic and nonphamacologic tber- 
apy in infancy and belii the two approaches are compfementaty and 
not competitive. AJtbougb viewpoints on the proper management of 
this entity are diverse it is important for us all to have a precise 
understanding of approaches that are divergent from our own. 
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Are tbe Drug Names Coumadin and 
Warfhrin Interchangeable? 
Nutnemus artidea pub&bed m several dit7erent journak over the past 
few years have negkted to capitafixe the letter “c” in Coumadin. a 
brand name of warfarin sodium manufadured hy Du Pont Pharma. 
ExamplesolthisourbefwmliocardiwascYlar(1-9,15-17),induding 
the Journal (136). as well as noncardmmmmar puhbshed reports 
(10-14). Although style fq4Tdkah for many of these journak 
dktatetbatdmgsbereferredtobytbeirgenericnames,theword 
“wumadin” often appears witbout reference to ?varfarin.” In one 
~theterm”ammadinderivatiwYisused(2).IsCotmtadm 
nowa~drug?lstheresuchathingasa“~m~derivative?” 
To cite some of the more recent examples, in the September 1995 
~oftheJoumalWcngetal.(l)evaluatedtbesafetyandefficacy 
ofPatmax-Schatxstentin@ntationiosapbenousveingraftlesioos.In 
that study, stent impbtation was followd by treatment with ‘km- 
mrnfinandd@r&mok.“fntbeApril1994issueoftheJoornaf,a 
stlQby+lisonetaf.(3)addmmedtfmtssneofusingpercotaneous 
ba&mmaiangiop~ofmpbmumswingraftfesJonsinpatients 
witbme4kdyrefmcto4yImsIaNeangina.Illtbestudyabstrad, 
;bciiuoctive~b$ctberaWconsistedot,amoogotlterdntgs, 
“wumadfn.” Hossever, iu the me- ‘+wahrs is lisled as 
"djunaivepbarmaccthe~~.WOUldtbiSiIllpIyfJUitcoumadin~ 
uaedexcGmly~tbmesmdics,oranddotherbrandsof 
W8IfXkIbavebeenUR?daSWdI?pubiisbedreportsOftheAPRJCOT 
~~~~,~~. *tb the original -eY coolpariop 
Toutndm (4)+andarmbquentIettertotbeeditor(5) 
andangiogmpbicanalysk(6)referringtoacompakmbehveen 
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Wby should practitioners Gtre about the semantics of “warfarin” 
versus ‘Coumadim?” In studii performed in the United States, 
“coumadin” is most IibeIy to be Coumadm because Du Pont Pbarma 
is currently the sole manufacturer of warfarin sodium in the United 
States. However, other brands of warfarin, for example, Panwar6n 
(warfarin sodium, Abbott Laboratories) and Sofarfn (warfarin potas- 
sium, Lemmon Company) were distributed in the United States until 
approximately 1990. Other countries have different brands of warfarin 
available as well, such as War&me (Frosst, Canada) and Waran 
(Nycomed, Norway). In the United Ringdom, until early 1995, two 
different companies bad heen manufactming warfarim Roebringer 
Ingelheim (Warfarin) and Goldshield (Marevan). fn addition, Couma- 
din is not the only available oral anticoagulant in the United States 
Dicumarol, another coumarin derivative, and anisindione (Miradon), 
an indandione derivative, are also available. 
Is thii to say that conclusions made regarding Coumadin cannot he 
extended to other brands of warfarin? Different oral anticoagulants 
have different pharmacologic properties, and difierent brands of 
warfarin may have ditfeting pbarmacokmetic variabks that may at&t 
indiidual patient response. For example, bioavaifability in individual 
subjects has been found to dither as much as 27% between brands of 
warfarin (IS). Therefore, clinical study results and application to 
practice may he atkcted by the type of oral anticoagtdant or brand of 
warfarin selected. As a more standardii measure of warfarin effq 
the target Jntemational Norma&d Ratios (WRs) and achieved fNRs 
should be reported in clinical research studies to better permit 
practitioners to apply dmical research rest& in tbeii patients. Wben 
matting reference to Coumadiq at a miniium, the first letter of the 
trade name should he capitalixed. Some editors may also use Comna- 
dma. The use of the term ‘warfarin” may be more appropriate in 
documents such as review articles and letters to the editor. which deaf 
with warfarin but are not specik for the Qumadin brand. 
Many authors and editors may continue to mabe the “coumadm” 
error because the word “Comnadio” has entered our daily conversa- 
tion about oral anticoagulation in a manner analogous to Kleenex 
facial tissues or Xerox photocopies. We even speab ahout “Cmmadi- 
nixing” patients. However, in the professional format of published 
medical reports, partktdarly in cardiovascular journals, we sboufd 
strive for accuracy in drug descriptions. The words “Coumadm” and 
“warfarin” are net necessarily interchangeable. 
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